RxDoctor Payments Data

Emily Haas

Nurse Practitioner · Sunbury, PANPI 1437571791

Payments from drug & device makers

$9,134in general payments, 2019–2025

Across 567 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$999
  • AbbVie$889
  • AstraZeneca$766
  • Amgen$652
  • GSK$550
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$9,128100%
  • Education$70%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,134 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

See all nurse practitioner providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$78,308
Medicare patients
142
Services billed
1,569

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin129$124,534
OzempicSemaglutide64$71,482
EliquisApixaban77$49,774
JanuviaSitagliptin Phosphate54$39,131
MyrbetriqMirabegron39$28,272
TrulicityDulaglutide13$27,296
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$24,048
Repatha SureclickEvolocumab16$22,895
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$22,447
XareltoRivaroxaban13$20,491
ProliaDenosumab11$18,125
Breo ElliptaFluticasone/Vilanterol22$16,720
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$11,693
VascepaIcosapent Ethyl28$10,897
TradjentaLinagliptin13$10,412

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$443$134,945142 claims
Novo NordiskOzempic$1,563$71,48264 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta$550$51,44874 claims
PfizerEliquis$546$49,77477 claims
MerckJanuvia$187$39,13154 claims
Astellas Pharma US IncMyrbetriq$259$28,27239 claims
Lilly USA, LLCTrulicity$999$27,29613 claims
AstraZenecaBreztri Aerosphere$766$24,04817 claims
Johnson & JohnsonXarelto$289$20,49113 claims
AmgenProlia$652$18,12511 claims
Sumitomo Pharma America, Inc.Gemtesa$36$5,31612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.

Other nurse practitioner in Sunbury

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →